These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload. von Bonsdorff M; Sipilä R; Pitkänen E Scand J Urol Nephrol Suppl; 1990; 131():49-54. PubMed ID: 2075470 [TBL] [Abstract][Full Text] [Related]
11. [Treatment with low doses of intravenous iron does not modify hemoglobin nor the erythropoietin dosage]. Fernández-Gallego J; Martín MA; Alonso A; Toledo R Nefrologia; 2006; 26(1):143-4. PubMed ID: 16649439 [No Abstract] [Full Text] [Related]
13. Aluminium interference in the treatment of haemodialysis patients with recombinant human erythropoietin. Casati S; Castelnovo C; Campise M; Ponticelli C Nephrol Dial Transplant; 1990; 5(6):441-3. PubMed ID: 2122321 [TBL] [Abstract][Full Text] [Related]
14. Plasma aluminium levels in patients on maintenance haemodialysis fall when oral aluminium hydroxide is withdrawn. Wallace MR; Pybus J N Z Med J; 1983 Oct; 96(742):793-5. PubMed ID: 6578451 [TBL] [Abstract][Full Text] [Related]
15. [Does aluminum affect the effectiveness of human recombinant erythropoietin in the treatment of anemia in dialyzed patients?]. Sulková S; Laurincová Z; Kvasnicka J Cas Lek Cesk; 1990 Jan; 129(4):113-5. PubMed ID: 2331725 [TBL] [Abstract][Full Text] [Related]
16. Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients. Cody J; Daly C; Campbell M; Donaldson C; Grant A; Khan I; Vale L; Wallace S; MacLeod A Cochrane Database Syst Rev; 2002; (4):CD003895. PubMed ID: 12519614 [TBL] [Abstract][Full Text] [Related]
17. Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease. Stevens ME; Summerfield GP; Hall AA; Beck CA; Harding AJ; Cove-Smith JR; Paterson AD BMJ; 1992 Feb; 304(6825):474-7. PubMed ID: 1547417 [TBL] [Abstract][Full Text] [Related]
19. Direct effect of deferoxamine on hemoglobin synthesis in patients on hemodialysis treated with recombinant human erythropoietin. Romero R; Novoa D; Otero S; Alonso MC; Alonso R; Arcocha V; Arza D; Lens XM; Sanchez-Guisande D Nephron; 1993; 63(2):164-7. PubMed ID: 8450906 [TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum. Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]